Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review
Hepatitis E is an acute self-limiting disease caused by hepatitis E virus (HEV). Recent reports show that HEV can induce chronic hepatitis or be reactivated in immunocompromised hosts. We report a 63-year-old woman with rheumatoid arthritis (RA) who developed hepatitis E during treatment with tocili...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2018/6873276 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691750342328320 |
|---|---|
| author | Hidekazu Ikeuchi Kana Koinuma Masao Nakasatomi Toru Sakairi Yoriaki Kaneko Akito Maeshima Yuichi Yamazaki Hiroaki Okamoto Toshihide Mimura Satoshi Mochida Yoshihisa Nojima Keiju Hiromura |
| author_facet | Hidekazu Ikeuchi Kana Koinuma Masao Nakasatomi Toru Sakairi Yoriaki Kaneko Akito Maeshima Yuichi Yamazaki Hiroaki Okamoto Toshihide Mimura Satoshi Mochida Yoshihisa Nojima Keiju Hiromura |
| author_sort | Hidekazu Ikeuchi |
| collection | DOAJ |
| description | Hepatitis E is an acute self-limiting disease caused by hepatitis E virus (HEV). Recent reports show that HEV can induce chronic hepatitis or be reactivated in immunocompromised hosts. We report a 63-year-old woman with rheumatoid arthritis (RA) who developed hepatitis E during treatment with tocilizumab. Analysis of serially stocked serum samples confirmed that hepatitis was caused by primary infection with HEV and not by viral reactivation. Her liver function improved after discontinuing tocilizumab and remained within the normal range without reactivation of HEV for >5 years after restarting tocilizumab. We also reviewed the published cases of hepatitis E that developed during RA treatment. |
| format | Article |
| id | doaj-art-b60e05677bdb439bb12c0c05936615dd |
| institution | DOAJ |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-b60e05677bdb439bb12c0c05936615dd2025-08-20T03:20:55ZengWileyCase Reports in Rheumatology2090-68892090-68972018-01-01201810.1155/2018/68732766873276Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature ReviewHidekazu Ikeuchi0Kana Koinuma1Masao Nakasatomi2Toru Sakairi3Yoriaki Kaneko4Akito Maeshima5Yuichi Yamazaki6Hiroaki Okamoto7Toshihide Mimura8Satoshi Mochida9Yoshihisa Nojima10Keiju Hiromura11Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, JapanDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, JapanDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, JapanDivision of Gastroenterology and Hepatology Internal Medicine, Saitama Medical University, Saitama, JapanDepartment of Rheumatology and Nephrology, Japan Red Cross Maebashi Hospital, Maebashi, JapanDepartment of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, JapanHepatitis E is an acute self-limiting disease caused by hepatitis E virus (HEV). Recent reports show that HEV can induce chronic hepatitis or be reactivated in immunocompromised hosts. We report a 63-year-old woman with rheumatoid arthritis (RA) who developed hepatitis E during treatment with tocilizumab. Analysis of serially stocked serum samples confirmed that hepatitis was caused by primary infection with HEV and not by viral reactivation. Her liver function improved after discontinuing tocilizumab and remained within the normal range without reactivation of HEV for >5 years after restarting tocilizumab. We also reviewed the published cases of hepatitis E that developed during RA treatment.http://dx.doi.org/10.1155/2018/6873276 |
| spellingShingle | Hidekazu Ikeuchi Kana Koinuma Masao Nakasatomi Toru Sakairi Yoriaki Kaneko Akito Maeshima Yuichi Yamazaki Hiroaki Okamoto Toshihide Mimura Satoshi Mochida Yoshihisa Nojima Keiju Hiromura Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review Case Reports in Rheumatology |
| title | Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review |
| title_full | Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review |
| title_fullStr | Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review |
| title_full_unstemmed | Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review |
| title_short | Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review |
| title_sort | hepatitis e during tocilizumab therapy in a patient with rheumatoid arthritis case report and literature review |
| url | http://dx.doi.org/10.1155/2018/6873276 |
| work_keys_str_mv | AT hidekazuikeuchi hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT kanakoinuma hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT masaonakasatomi hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT torusakairi hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT yoriakikaneko hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT akitomaeshima hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT yuichiyamazaki hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT hiroakiokamoto hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT toshihidemimura hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT satoshimochida hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT yoshihisanojima hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview AT keijuhiromura hepatitiseduringtocilizumabtherapyinapatientwithrheumatoidarthritiscasereportandliteraturereview |